## Diagnosis & Clinical Context **Key Point:** This patient has visceral leishmaniasis (kala-azar) confirmed by: - Endemic region (Bihar — high-prevalence area in India) - Classic triad: fever, hepatosplenomegaly, pancytopenia - Bone marrow amastigotes (diagnostic gold standard) ## First-Line Treatment Hierarchy | Drug | Status | Notes | |------|--------|-------| | **Liposomal amphotericin B** | **First-line (WHO/India)** | **Efficacy >95%, rapid response, safe** | | Sodium stibogluconate | Second-line (resistance ↑) | Older agent; 20–30% treatment failure in Bihar | | Amphotericin B deoxycholate | Older formulation | Nephrotoxicity, less preferred than liposomal | | Miltefosine | Alternative (oral) | Slower onset; teratogenic; used for relapse/resistance | ## Why Liposomal Amphotericin B? **High-Yield:** Liposomal amphotericin B is the **current WHO and Indian guidelines (2023) first-line agent** for visceral leishmaniasis because: 1. **Efficacy:** >95% cure rate, even in antimony-resistant cases 2. **Rapid parasite clearance:** Fever subsides within 3–7 days 3. **Safety:** Encapsulation reduces nephrotoxicity vs. deoxycholate form 4. **Dosing:** 3 mg/kg IV on days 1–5, 10, 17, 24, 31, 38 (total 30 mg/kg) **Clinical Pearl:** In India, particularly Bihar and eastern regions, sodium stibogluconate resistance is now **endemic** (>20–30% failure rate), making it unsuitable as monotherapy despite historical use. **Mnemonic:** **LAB-VL** = **L**iposomal **A**mphotericin **B** for **V**isceral **L**eishmaniasis (first-line) ## Alternative Agents (Context) - **Miltefosine:** Oral option; slower (4–6 weeks); reserved for relapse, resistance, or when IV access unavailable - **Amphotericin B deoxycholate:** Older; nephrotoxic; used only if liposomal unavailable - **Sodium stibogluconate:** Historically first-line; now second-line due to resistance emergence [cite:Park 26e Ch 3]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.